CLAIMS

1. Use of a peptide in the manufacture of a medicament for modulating bile acid homeostasis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:70 (M70), and wherein the subject has primary biliary cirrhosis (PBC), cholestasis, primary sclerosing cholangitis (PSC), bile acid diarrhea (BAD), pregnancy intrahepatic cholestasis (PIC), bile acid malabsorption, or nonalcoholic steatohepatitis (NASH).

2. The use of claim 1, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:70.

3. Use of a peptide in the manufacture of a medicament for modulating bile acid homeostasis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:69 (M69), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, or NASH.

4. The use of claim 3, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:69.

5. Use of a peptide in the manufacture of a medicament for modulating bile acid homeostasis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:1 (M1), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, or NASH.

6. The use of claim 5, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:1.

7. Use of a peptide in the manufacture of a medicament for modulating bile acid homeostasis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:2 (M2), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, or NASH.

8. The use of claim 7, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:2.

9. The use of any one of claims 1 to 8, wherein the peptide is fused with an immunoglobulin Fc region.

10. The use of any one of claims 1 to 9, wherein the peptide is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

11. The use of any one of claims 1 to 10, wherein the medicament is prepared for administration to the subject in combination with a supplemental therapy.

12. The use of any one of claims 1 to 11, wherein the subject has PBC.

13. The use of any one of claims 1 to 11, wherein the subject has cholestasis.

14. The use of any one of claims 1 to 11, wherein the subject has PSC.

15. The use of any one of claims 1 to 11, wherein the subject has BAD.

16. The use of any one of claims 1 to 11, wherein the subject has PIC.

17. The use of any one of claims 1 to 11, wherein the subject has bile acid malabsorption.

18. The use of any one of claims 1 to 11, wherein the subject has NASH.

19. Use of a peptide in the manufacture of a medicament for reducing bile acid synthesis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:70 (M70), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, or NASH.

20. The use of claim 19, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:70.

21. Use of a peptide in the manufacture of a medicament for reducing bile acid synthesis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:69

(M69), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, or NASH.

22. The use of claim 21, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:69.

23. Use of a peptide in the manufacture of a medicament for reducing bile acid synthesis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:1 (M1), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, or NASH.

24. The use of claim 23, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:1.

25. Use of a peptide in the manufacture of a medicament for reducing bile acid synthesis in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:2 (M2), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, or NASH.

26. The use of claim 25, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:2.

27. The use of any one of claims 19 to 26, wherein the peptide is fused with an immunoglobulin Fc region.

28. The use of any one of claims 19 to 27, wherein the peptide is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

29. The use of any one of claims 19 to 28, wherein the medicament is prepared for administration to the subject in combination with a supplemental therapy.

30. The use of any one of claims 19 to 29, wherein the subject has PBC.

31. The use of any one of claims 19 to 29, wherein the subject has cholestasis.

32. The use of any one of claims 19 to 29, wherein the subject has PSC.

33. The use of any one of claims 19 to 29, wherein the subject has BAD.

34. The use of any one of claims 19 to 29, wherein the subject has PIC.

35. The use of any one of claims 19 to 29, wherein the subject has bile acid malabsorption.

36. The use of any one of claims 19 to 29, wherein the subject has NASH.

37. Use of a peptide in the manufacture of a medicament for reducing CYP7A1 levels in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:70 (M70), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, or NASH.

38. The use of claim 37, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:70.

39. Use of a peptide in the manufacture of a medicament for reducing CYP7A1 levels in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:69 (M69), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, or NASH.

40. The use of claim 39, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:69.

41. Use of a peptide in the manufacture of a medicament for reducing CYP7A1 levels in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:1 (M1), and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, or NASH.

42. The use of claim 41, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:1.

43. Use of a peptide in the manufacture of a medicament for reducing CYP7A1 levels in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:2 (M2),

and wherein the subject has PBC, cholestasis, PSC, BAD, PIC, bile acid malabsorption, or NASH.

44. The use of claim 43, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:2.

45. The use of any one of claims 37 to 44, wherein the peptide is fused with an immunoglobulin Fc region.

46. The use of any one of claims 37 to 45, wherein the peptide is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

47. The use of any one of claims 37 to 46, wherein the medicament is prepared for administration to the subject in combination with a supplemental therapy.

48. The use of any one of claims 37 to 47, wherein the subject has PBC.

49. The use of any one of claims 37 to 47, wherein the subject has cholestasis.

50. The use of any one of claims 37 to 47, wherein the subject has PSC.

51. The use of any one of claims 37 to 47, wherein the subject has BAD.

52. The use of any one of claims 37 to 47, wherein the subject has PIC.

53. The use of any one of claims 37 to 47, wherein the subject has bile acid malabsorption.

54. The use of any one of claims 37 to 47, wherein the subject has NASH.

55. Use of a peptide in the manufacture of a medicament for the treatment of NASH in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:70 (M70).

56. The use of claim 55, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:70.

57. The use of claim 55 or 56, wherein the peptide is fused with an immunoglobulin Fc region.

58. The use of any one of claims 55 to 57, wherein the peptide is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

59. The use of any one of claims 55 to 58, wherein the medicament is prepared for administration to the subject in combination with a supplemental therapy.

60. Use of a peptide in the manufacture of a medicament for the treatment of PBC in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:70 (M70).

61. The use of claim 60, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:70.

62. The use of claim 60 or 61, wherein the peptide is fused with an immunoglobulin Fc region.

63. The use of any one of claims 60 to 62, wherein the peptide is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

64. The use of any one of claims 60 to 63, wherein the medicament is prepared for administration to the subject in combination with a supplemental therapy.

65. Use of a peptide in the manufacture of a medicament for the treatment of PSC in a subject, wherein the peptide has an amino acid sequence comprising SEQ ID NO:70 (M70).

66. The use of claim 65, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:70.

67. The use of claim 65 or 66, wherein the peptide is fused with an immunoglobulin Fc region.

68. The use of any one of claims 65 to 67, wherein the peptide is formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

69. The use of any one of claims 65 to 68, wherein the medicament is prepared for administration to the subject in combination with a supplemental therapy.